诺华2024年收入同比增长12% Pluvicto成全球核药赛道中首个“重磅炸弹”

每日经济新闻
06 Feb

在全球核药布局竞赛中,首款年销超10亿美元的重磅药物诞生了。  近日,“核药王者”诺华公布2024年业绩,公司全年实现营收503.17亿美元,同比增长12%。两款核药合计收入首次突破20美元,其中Pluvicto成为全球核药赛道中首款“重磅炸弹”。在创新药领域,年销售额达到10亿美元的药物常常被称为“重磅炸弹”。  去年,诺华共有14款年销超10亿美元的重磅药物,上市4年的超长效降脂药物乐可为(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10